Blendis, L M

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

Zelber–Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., Leshno, M., Blendis, L., Halpern, Z., & Oren, R. (2006) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentPharmacology and Obesity Treatment

Cited by 317

Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?

Kilmurry, M. R., Heathcote, E. J., Cauch-Dudek, K., O’Rourke, K., Bailey, R. J., Blendis, L. M., Ghent, C. N., Minuk, G. Y., Pappas, S. C., Scully, L. J., et al. (1996) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 94

Plasma neutral amino acid ratios in normal man and in patients with hepatic encephalopathy: correlations with self-selected protein and energy consumption

Anderson, G. H., & Blendis, L. M. (1981) · The American Journal of Clinical Nutrition

Muscle metabolism and nutritionClinical Nutrition and Gastroenterology

Cited by 17

The Canadian Multicenter Double‐blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis

Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., et al. (1994) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 2